CA
NZ
UK
AU
IND
US
• First-quarter 2026 revenue reached $1.42 billion, topping estimates, with earnings per share of $2.94 against consensus of $0.93.
• The stock benefited from a broader sector rotation into healthcare and medical technology names.
• NeuroOne Medical Technology has drawn fresh market attention following a notable share-price decline that has weighed on investor sentiment.
• Heartflow has drawn market attention after a notable share-price decline that followed a difficult trading session.
• Lexicon Pharmaceuticals has drawn fresh market attention after renewed share-price weakness that has tested investor sentiment.
• Lixte Biotechnology has drawn market attention after a share-price decline that has weighed on clinical-stage biotech sentiment.
• Moleculin Biotech has drawn renewed market attention after a share-price decline that has prompted a fresh check on investor confidence.
• Aspire Biopharma has drawn heightened market attention after a share-price slide that amounts to a fresh test in a demanding biotech environment.
• Can-Fite BioPharma Ltd. (NYSE: CANF) reported that its Phase 2a study of Namodenoson in advanced pancreatic ductal adenocarcinoma met its primary safety endpoint and showed durable overall survival.
• What They Are: Pre-funded warrants let investors pay for shares upfront and exercise later at a nominal price, near zero.
Please wait processing your request...